Clinic
Matagorda County Hospital District
Matagorda County Hospital District was paid $3.87M by Medicaid between Jan 2020 and Nov 2024, across 85 billing codes. Its largest line is 99284, emergency room visit (serious) — 36% of everything it billed.
33Billing provider infoMATAGORDA COUNTY HOSPITAL DISTRICT
BAY CITY, TX 77414
BAY CITY, TX 77414
33aNPI1679678767assigned 09/13/2006
33bProvider typeAmbulatory Surgical Clinic/Center
28Total paid$3.87M
24GClaims102,191
24DCodes billed85
24AFirst – last monthJan 2020 – Nov 2024
Compared with peers
Next to other Ambulatory Surgical Clinic/Center providers in Texas
Rank by total paid#93 of 320
Median peer was paid$205K
This provider vs. median19×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2020 | 2,774 | $75K | |
| 2021 | 26,649 | $705K | |
| 2022 | 30,418 | $1.10M | |
| 2023 | 30,795 | $1.35M | |
| 2024incomplete | 11,555 | $637K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 36% | 5,527 | 5,090 | $1.40M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 33% | 8,161 | 7,803 | $1.26M |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 5.3% | 1,649 | 1,606 | $204K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 2.4% | 5,133 | 4,954 | $94K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 2.4% | 2,598 | 2,532 | $94K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 2.2% | 1,485 | 1,324 | $85K |
| 71045 | Radiologic examination, chest; single view | 1.8% | 1,396 | 1,299 | $70K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.7% | 11,818 | 10,316 | $67K |
| 86901 | 1.7% | 516 | 465 | $66K | |
| 80053 | Comprehensive metabolic panel | 1.2% | 7,291 | 6,294 | $46K |
| 86900 | 1.1% | 491 | 465 | $44K | |
| 87806 | 1.1% | 1,302 | 1,268 | $42K |
73 more codes
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 726 | $36K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 564 | $36K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 986 | $35K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 619 | $23K |
| 87088 | <1% | 3,043 | $20K | |
| 99285 | Emergency room visit (most serious) | <1% | 128 | $19K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,559 | $15K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 82 | $14K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 365 | $13K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 363 | $13K |
| 81001 | <1% | 5,041 | $12K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 83 | $12K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 1,062 | $12K |
| 83880 | <1% | 1,250 | $11K | |
| 86885 | <1% | 1,543 | $9K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 214 | $8K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 961 | $8K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 575 | $7K |
| 80061 | Lipid panel | <1% | 1,546 | $7K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 89 | $7K |
| 86592 | <1% | 1,463 | $6K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,485 | $6K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 1,194 | $5K |
| 87340 | <1% | 430 | $4K | |
| 84484 | <1% | 1,197 | $4K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 51 | $4K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 249 | $3K |
| 86762 | <1% | 259 | $3K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 27 | $3K |
| 81025 | <1% | 333 | $3K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 53 | $3K |
| 84439 | <1% | 309 | $3K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,116 | $3K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 20 | $3K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 157 | $2K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 584 | $2K |
| 87653 | <1% | 54 | $2K | |
| 87077 | <1% | 610 | $2K | |
| 87186 | <1% | 568 | $2K | |
| 83690 | <1% | 634 | $2K | |
| 85610 | <1% | 856 | $2K | |
| 85730 | <1% | 695 | $2K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 16 | $2K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 304 | $1K |
| 82947 | <1% | 564 | $1K | |
| CP008 | <1% | 29 | $1K | |
| 82553 | <1% | 391 | $1K | |
| 83735 | <1% | 423 | $1K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 38 | $919.55 |
| 82550 | <1% | 583 | $910.63 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 46 | $879.33 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 736 | $843.65 |
| 36415 | Collection of venous blood by venipuncture | <1% | 16,551 | $806.59 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 142 | $622.13 |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 29 | $565.80 |
| 87040 | <1% | 84 | $461.72 | |
| 83655 | <1% | 24 | $343.35 | |
| 84702 | <1% | 16 | $321.54 | |
| 83605 | <1% | 82 | $284.37 | |
| 82950 | <1% | 40 | $213.96 | |
| 84703 | <1% | 27 | $189.26 | |
| 86787 | <1% | 12 | $167.76 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 172 | $108.96 |
| 82607 | <1% | 17 | $44.10 | |
| 82728 | <1% | 17 | $39.84 | |
| 82746 | <1% | 16 | $21.49 | |
| 83550 | <1% | 16 | $12.77 | |
| 85652 | <1% | 12 | $10.32 | |
| 83540 | <1% | 34 | $9.45 | |
| P9604 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge | 0% | 1,208 | $0.00 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 28 | $0.00 |
| J2704 | Injection, propofol, 10 mg | 0% | 12 | $0.00 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialPROCHNOW, BRYAN (CFO)